Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 5:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sarcoma,Soft Tissue Clear all
Completed Phase 1 Interventional

Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer

NCT01445379
View directory record Official record
Conditions
Sarcoma, Wilm's Tumor, Lymphoma, Neuroblastoma
Interventions
Ipilimumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 21 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
3
States / cities
Bethesda, Maryland • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 20, 2026, 5:43 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

NCT04094610
View directory record Official record
Conditions
Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
Interventions
Oral repotrectinib (TPX-0005)
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
Up to 25 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
20
States / cities
Los Angeles, California • Aurora, Colorado • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Recruiting Not applicable Interventional

Individualized Prehabilitation for Enhancing Recovery and Surgical Outcomes in Patients Undergoing Radiotherapy and Surgery for Soft Tissue Sarcoma

NCT05526417
View directory record Official record
Conditions
Soft Tissue Sarcoma, Stage I Soft Tissue Sarcoma of the Trunk and Extremities, Stage II Soft Tissue Sarcoma of the Trunk and Extremities, Stage III Soft Tissue Sarcoma of the Trunk and Extremities
Interventions
Computed Tomography, Educational Intervention, Magnetic Resonance Imaging, Physical Therapy, Questionnaire Administration, Telemedicine
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Not yet recruiting Phase 2 Interventional

The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma

NCT07560826
View directory record Official record
Conditions
Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
Interventions
High-dose Methotrexate
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
7 Years to 22 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study

NCT00611078
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 79 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2011 · Synced Sep 20, 2026, 5:43 AM EDT
Recruiting Phase 2 Interventional

A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

NCT04872543
View directory record Official record
Conditions
Malignant Peripheral Nerve Sheath Tumors (MPNST)
Interventions
ASTX727
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 3 Interventional

A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.

NCT00002093
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Daunorubicin (liposomal), Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride
Drug
Lead sponsor
Nexstar Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palm Springs, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Study in Advanced Solid Tumors

NCT01099358
View directory record Official record
Conditions
Solid Tumor
Interventions
Cetuximab, Cisplatin, 5 - Fluorouracil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
5
States / cities
Fayetteville, Arkansas • Fairway, Kansas • Reno, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma

NCT01879085
View directory record Official record
Conditions
Sarcoma
Interventions
Docetaxel, Gemcitabine, Vorinostat, Pegfilgrastim
Drug
Lead sponsor
Melissa Burgess, MD
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 20, 2026, 5:43 AM EDT
Terminated Phase 2 Interventional Results available

QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma

NCT03132155
View directory record Official record
Conditions
Clear Cell Sarcoma
Interventions
AMG 337
Drug
Lead sponsor
NantPharma, LLC
Industry
Eligibility
16 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
El Segundo, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

NCT01477021
View directory record Official record
Conditions
Adult Liposarcoma, Adult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
cyclophosphamide, NY-ESO-1-specific T cells, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 20, 2026, 5:43 AM EDT
Terminated Phase 2 Interventional Results available

Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall

NCT00089544
View directory record Official record
Conditions
Recurrent Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7, Stage II Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7
Interventions
Dacarbazine, Doxorubicin Hydrochloride, Filgrastim, Ifosfamide, Laboratory Biomarker Analysis, Radiation Therapy, Thalidomide, Therapeutic Conventional Surgery
Drug · Biological · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

NCT02223052
View directory record Official record
Conditions
Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary
Interventions
CC-486, Vidaza
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 20, 2026, 5:43 AM EDT
Recruiting Phase 2 Interventional

Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas

NCT04506008
View directory record Official record
Conditions
Soft Tissue Sarcomas
Interventions
Ultra-Hypo-fractionation Radiotherapy, Resection, Questionnaire Administration, Moderately-Hypo-fractionation Radiotherapy
Radiation · Procedure · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

NCT02097238
View directory record Official record
Conditions
Recurrent Osteosarcoma
Interventions
Eribulin Mesylate, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 49 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
116
States / cities
Birmingham, Alabama • Phoenix, Arizona • Downey, California + 76 more
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

Twins Study of Gene Therapy for HIV Infection

NCT00001535
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infection, Kaposi's Sarcoma
Interventions
Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2008 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma

NCT03006848
View directory record Official record
Conditions
Osteosarcoma
Interventions
Avelumab, Questionnaires
Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 49 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Active, not recruiting No phase listed Observational

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

NCT05812027
View directory record Official record
Conditions
Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma
Interventions
Tumor and HLA Profiling
Diagnostic Test
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
21
States / cities
Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 20, 2026, 5:43 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Radiation Therapy Before Surgery for Localized, Resectable Soft Tissue Sarcoma of the Extremity and Superficial Trunk

NCT04562480
View directory record Official record
Conditions
Resectable Soft Tissue Sarcoma, Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Interventions
Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Resection
Radiation · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

NCT01391962
View directory record Official record
Conditions
Sarcoma, Alveolar Soft Part
Interventions
Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 2 Interventional

Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00064142
View directory record Official record
Conditions
AIDS-related Kaposi Sarcoma, Recurrent Kaposi Sarcoma
Interventions
halofuginone hydrobromide, placebo, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 20, 2026, 5:43 AM EDT
Active, not recruiting Phase 2 Interventional

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

NCT03967223
View directory record Official record
Conditions
Neoplasms
Interventions
Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide
Drug
Lead sponsor
USWM CT, LLC
Industry
Eligibility
10 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
24
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

Cathepsin Activatable Fluorescent Probe

NCT01626066
View directory record Official record
Conditions
Sarcoma, Soft Tissue Sarcoma, Breast Cancer
Interventions
LUM015
Drug
Lead sponsor
David Kirsch
Other
Eligibility
18 Years to 74 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Not applicable Interventional

Caspofungin Acetate in Treating Children With Fever and Neutropenia

NCT00020527
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Infection, Kidney Cancer, Leukemia, Lymphoma, Neuroblastoma, Neutropenia, Sarcoma
Interventions
caspofungin acetate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 20, 2026, 5:43 AM EDT